Published December 17, 2003 | Version v1
Journal article

The development of the Canberra symptom scorecard: a tool to monitor the physical symptoms of patients with advanced tumours

  • 1. Centre for Advances in Epidemiology and Information Technology, The Canberra Hospital, Woden, Canberra, ACT 2606 (Australia)
  • 2. School of Psychology, The Australian National University, Canberra, ACT 0200 (Australia)
  • 3. Medical Oncology Unit, The Canberra Hospital, Woden, Canberra, ACT 2606 (Australia)

Description

Patients with advanced (incurable) tumours usually experience a diverse burden of symptoms. Although many symptom assessment instruments are available, we examined whether these addressed tumour-related symptoms. We reviewed existing symptom assessment instruments and found a number of deficiencies such as instruments being too long or burdensome, too short, or measuring quality of life rather than tumour-related symptoms. Others focused on emotional, rather than physical symptoms. Therefore, we decided to devise a new symptom instrument. A list of 20 symptoms common in patients with advanced tumours generated from the literature and existing instruments, was ranked according to prevalence by 202 Australian clinicians. Following clinicians' responses, the list was revised and two severity assessment scales (functional severity and distress severity) added. The resultant 18-item list was assessed in 44 outpatients with advanced tumours. Patient responses indicated that a shorter questionnaire of 11 items, reflecting three main symptom clusters, provided a good representation of physical symptoms. An additional symptom that is an important predictor of survival was added, making a 12-item questionnaire, which was entitled 'The Canberra Symptom Scorecard' (CSS). For symptom severity, the distress severity scale was more appropriate than the functional severity scale. The CSS focuses on tumour-related physical symptoms. It is about to be assessed in patients with advanced tumours receiving palliative treatments, when it will also be validated against existing instruments

Availability note (English)

Available from http://dx.doi.org/10.1186/1471-2407-3-32; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC317311

Additional details

Publishing Information

Journal Title
BMC cancer (Online)
Journal Volume
3
Journal Page Range
p. 32
ISSN
1471-2407

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
46082191
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CHARGES; NEOPLASMS; PATIENTS; STANDARD OF LIVING; SYMPTOMS
Descriptors DEC
DISEASES

Optional Information

Copyright
Copyright (c) 2003 Barresi et al
Notes
PMCID: PMC317311; PUBLISHER-ID: 1471-2407-3-32; PMID: 14678564; OAI: oai:pubmedcentral.nih.gov:317311; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.